Immunome, Inc.
IMNM
$8.49
$0.030.36%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -13.76% | -35.50% | -0.62% | 62.73% | 436.51% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -13.76% | -35.50% | -0.62% | 62.73% | 436.51% |
| Cost of Revenue | 337.24% | 461.06% | 416.78% | 204.05% | 87.67% |
| Gross Profit | -540.87% | -1,228.42% | -986.04% | -279.45% | -36.27% |
| SG&A Expenses | 65.52% | 67.65% | 101.10% | 79.55% | 76.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 229.38% | 280.15% | 270.82% | 150.99% | 83.12% |
| Operating Income | -298.52% | -434.17% | -392.89% | -173.01% | -54.24% |
| Income Before Tax | 11.60% | -174.29% | -1,290.60% | -904.33% | -686.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 11.60% | -174.29% | -1,290.60% | -904.33% | -686.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.60% | -174.29% | -1,290.60% | -904.33% | -686.19% |
| EBIT | -298.52% | -434.17% | -392.89% | -173.01% | -54.24% |
| EBITDA | -298.63% | -437.26% | -396.07% | -173.41% | -54.60% |
| EPS Basic | 41.94% | -55.52% | -235.99% | -155.82% | -121.02% |
| Normalized Basic EPS | -77.41% | -63.35% | 1.06% | 31.68% | 39.63% |
| EPS Diluted | 41.88% | -55.64% | -235.64% | -155.60% | -120.49% |
| Normalized Diluted EPS | -77.41% | -63.35% | 1.06% | 31.68% | 39.63% |
| Average Basic Shares Outstanding | 120.99% | 195.47% | 340.31% | 242.29% | 144.48% |
| Average Diluted Shares Outstanding | 120.99% | 195.47% | 340.31% | 242.29% | 144.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |